Profusa is pioneering tissue-integrating biosensors for continuous monitoring of body chemistries.
DARPA-Backed Study Leverages Profusa’s Lumee® Oxygen Platform as Part of a Larger Effort to Speed Detection and Predict ...
New Insights Come as Profusa Receives CE Mark for Its Latest Generation Device, the Wireless Lumee® Oxygen Platform ...
Next-Generation Wireless Device May Enable Telehealth And Remote Patient Monitoring in the Future EMERYVILLE, Calif., [January 28, 2020] ...
Awarded 2018 Entrepreneurial Company of the Year for real-time body chemistry monitoring South San Francisco, Calif. – October ...
Profusa Software and Systems Lead, Kevin Zhao, has been selected to participate in the Defense Advanced Research Projects ...
Leading global investors join this round; financing will accelerate commercialization of Lumee™ Oxygen Platform and pioneering glucose biosensors ...
Novel microsensing technology that reflects microvascular perfusion and oxygen supply in tissue shows promise in patients with chronic limb-threatening ischemia.
NEW ORLEANS, March 19, 2018 — Up until now, local inflammation and scar tissue from the so-called “foreign body response” has prevented ...